A retrospective analysis conducted at our center show that for patients with HR + /HER2- breast cancer, switching to a non-cross-resistant regimen after NCT (containing anthracycline or taxane) could have better distant disease-free survival (DDFS) (unpublished data). The gene discussed is ERBB2; the disease is breast cancer.